Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 4/10

vs
industry
vs
history
Cash to Debt 3.75
EPGNF's Cash to Debt is ranked higher than
51% of the 181 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.74 vs. EPGNF: 3.75 )
Ranked among companies with meaningful Cash to Debt only.
EPGNF' s 10-Year Cash to Debt Range
Min: 1.73  Med: 9999.00 Max: 11742.5
Current: 3.75
1.73
11742.5
Equity to Asset 0.41
EPGNF's Equity to Asset is ranked lower than
76% of the 165 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.61 vs. EPGNF: 0.41 )
Ranked among companies with meaningful Equity to Asset only.
EPGNF' s 10-Year Equity to Asset Range
Min: 0.39  Med: 0.75 Max: 0.98
Current: 0.41
0.39
0.98
F-Score: 3
Z-Score: 0.23
M-Score: -4.02
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 2/10

vs
industry
vs
history
Operating margin (%) -650.27
EPGNF's Operating margin (%) is ranked lower than
89% of the 176 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -0.26 vs. EPGNF: -650.27 )
Ranked among companies with meaningful Operating margin (%) only.
EPGNF' s 10-Year Operating margin (%) Range
Min: -1166.79  Med: -475.99 Max: 130.51
Current: -650.27
-1166.79
130.51
Net-margin (%) -666.01
EPGNF's Net-margin (%) is ranked lower than
90% of the 176 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -1.51 vs. EPGNF: -666.01 )
Ranked among companies with meaningful Net-margin (%) only.
EPGNF' s 10-Year Net-margin (%) Range
Min: -1173.92  Med: -470.61 Max: 138.38
Current: -666.01
-1173.92
138.38
ROE (%) -194.16
EPGNF's ROE (%) is ranked lower than
90% of the 168 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -1.52 vs. EPGNF: -194.16 )
Ranked among companies with meaningful ROE (%) only.
EPGNF' s 10-Year ROE (%) Range
Min: -140.91  Med: -65.61 Max: 21.77
Current: -194.16
-140.91
21.77
ROA (%) -95.73
EPGNF's ROA (%) is ranked lower than
87% of the 183 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -2.53 vs. EPGNF: -95.73 )
Ranked among companies with meaningful ROA (%) only.
EPGNF' s 10-Year ROA (%) Range
Min: -92.61  Med: -55.81 Max: 25.95
Current: -95.73
-92.61
25.95
ROC (Joel Greenblatt) (%) -1326.05
EPGNF's ROC (Joel Greenblatt) (%) is ranked lower than
86% of the 181 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -2.58 vs. EPGNF: -1326.05 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
EPGNF' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -2903.81  Med: -1306.33 Max: 249.81
Current: -1326.05
-2903.81
249.81
Revenue Growth (3Y)(%) -11.70
EPGNF's Revenue Growth (3Y)(%) is ranked lower than
76% of the 111 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 6.10 vs. EPGNF: -11.70 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
EPGNF' s 10-Year Revenue Growth (3Y)(%) Range
Min: -45.3  Med: -11.70 Max: 17
Current: -11.7
-45.3
17
EBITDA Growth (3Y)(%) -23.30
EPGNF's EBITDA Growth (3Y)(%) is ranked lower than
79% of the 100 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.90 vs. EPGNF: -23.30 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
EPGNF' s 10-Year EBITDA Growth (3Y)(%) Range
Min: -30.2  Med: 0.85 Max: 57.9
Current: -23.3
-30.2
57.9
EPS Growth (3Y)(%) -28.40
EPGNF's EPS Growth (3Y)(%) is ranked lower than
78% of the 99 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.60 vs. EPGNF: -28.40 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
EPGNF' s 10-Year EPS Growth (3Y)(%) Range
Min: -28.4  Med: 0.10 Max: 58
Current: -28.4
-28.4
58
» EPGNF's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Insider Trades

Latest Guru Trades with EPGNF

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/B 18.29
EPGNF's P/B is ranked lower than
94% of the 166 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.47 vs. EPGNF: 18.29 )
Ranked among companies with meaningful P/B only.
EPGNF' s 10-Year P/B Range
Min: 0.64  Med: 2.97 Max: 22.83
Current: 18.29
0.64
22.83
P/S 51.20
EPGNF's P/S is ranked lower than
94% of the 174 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.00 vs. EPGNF: 51.20 )
Ranked among companies with meaningful P/S only.
EPGNF' s 10-Year P/S Range
Min: 4.12  Med: 18.96 Max: 61.3
Current: 51.2
4.12
61.3
Current Ratio 1.95
EPGNF's Current Ratio is ranked lower than
65% of the 175 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.80 vs. EPGNF: 1.95 )
Ranked among companies with meaningful Current Ratio only.
EPGNF' s 10-Year Current Ratio Range
Min: 1.35  Med: 2.69 Max: 11.77
Current: 1.95
1.35
11.77
Quick Ratio 1.65
EPGNF's Quick Ratio is ranked lower than
63% of the 175 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.39 vs. EPGNF: 1.65 )
Ranked among companies with meaningful Quick Ratio only.
EPGNF' s 10-Year Quick Ratio Range
Min: 1.15  Med: 2.66 Max: 11.74
Current: 1.65
1.15
11.74
Days Inventory 400.67
EPGNF's Days Inventory is ranked lower than
98% of the 140 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 82.37 vs. EPGNF: 400.67 )
Ranked among companies with meaningful Days Inventory only.
EPGNF' s 10-Year Days Inventory Range
Min: 7.67  Med: 91.04 Max: 256.65
Current: 400.67
7.67
256.65
Days Sales Outstanding 28.10
EPGNF's Days Sales Outstanding is ranked higher than
92% of the 155 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 65.73 vs. EPGNF: 28.10 )
Ranked among companies with meaningful Days Sales Outstanding only.
EPGNF' s 10-Year Days Sales Outstanding Range
Min: 29.38  Med: 66.83 Max: 110.31
Current: 28.1
29.38
110.31

Valuation & Return

vs
industry
vs
history
Price/Net Cash 256.00
EPGNF's Price/Net Cash is ranked lower than
100% of the 61 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 10.55 vs. EPGNF: 256.00 )
Ranked among companies with meaningful Price/Net Cash only.
EPGNF' s 10-Year Price/Net Cash Range
Min: 1.03  Med: 4.71 Max: 283.8
Current: 256
1.03
283.8
Price/Net Current Asset Value 36.57
EPGNF's Price/Net Current Asset Value is ranked lower than
88% of the 103 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 7.07 vs. EPGNF: 36.57 )
Ranked among companies with meaningful Price/Net Current Asset Value only.
EPGNF' s 10-Year Price/Net Current Asset Value Range
Min: 0.91  Med: 4.00 Max: 89.2
Current: 36.57
0.91
89.2
Price/Tangible Book 25.60
EPGNF's Price/Tangible Book is ranked lower than
93% of the 143 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 4.96 vs. EPGNF: 25.60 )
Ranked among companies with meaningful Price/Tangible Book only.
EPGNF' s 10-Year Price/Tangible Book Range
Min: 0.85  Med: 3.77 Max: 29.73
Current: 25.6
0.85
29.73
Price/Median PS Value 2.71
EPGNF's Price/Median PS Value is ranked lower than
93% of the 153 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.09 vs. EPGNF: 2.71 )
Ranked among companies with meaningful Price/Median PS Value only.
EPGNF' s 10-Year Price/Median PS Value Range
Min: 0.28  Med: 1.04 Max: 3
Current: 2.71
0.28
3
Earnings Yield (Greenblatt) (%) -11.40
EPGNF's Earnings Yield (Greenblatt) (%) is ranked lower than
76% of the 178 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -0.50 vs. EPGNF: -11.40 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
EPGNF' s 10-Year Earnings Yield (Greenblatt) (%) Range
Min: 81.4  Med: 105.45 Max: 2135.3
Current: -11.4
81.4
2135.3

Business Description

Industry: Medical Diagnostics & Research » Diagnostics & Research
Compare: » details
Traded in other countries:0QXH.UK, ECX.Germany,
Epigenomics AG was founded as a limited liability company (GmbH) in 1998. The Company develop and markets procedures and devices for the production in quantity of particular epigenetic parameters such as DNA methylation patterns as well as the information technology bases necessary for their procurement and evaluation. It is engaged in the development of novel molecular diagnostic products for cancer.
» More Articles for EPGNF

Headlines

Articles On GuruFocus.com
No related article found.

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK